Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Salvat, Lees Pharmaceutical Holdings Ltd. deal

    Laboratorios Salvat S.A., Barcelona, Spain Lees Pharmaceutical Holdings Ltd. (HKSE:0950), Hong Kong, China Business: Infectious Salvat granted Lees exclusive rights to develop and commercialize Duoxal ciprofloxacin plus…

    Published on 2/1/2016
  • Spectrum Pharmaceuticals, Servier deal

    Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Servier, Neuilly-sur-Seine, France Business: Cancer Spectrum granted Serviers Servier Canada Inc. affiliate exclusive, Canadian rights to develop and …

    Published on 2/1/2016
  • University of Texas MD Anderson Cancer Center, AbbVie deal

    University of Texas MD Anderson Cancer Center, Houston, Texas AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer MD Anderson and AbbVie partnered for three years to develop immuno-oncology candidates. Each partner …

    Published on 2/1/2016
  • 4D Molecular Therapeutics, Pfizer deal

    4D Molecular Therapeutics LLC, Emeryville, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cardiovascular 4D partnered with Pfizer to discover, develop and commercialize next-generation adeno-associated viral (…

    Published on 1/25/2016
  • Actelion, Vipergen deal

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Vipergen ApS, Copenhagen, Denmark Business: Pharmaceuticals Vipergen will use its small molecule discovery platform to identify hits and leads for undisclosed targets …

    Published on 1/25/2016
  • Amgen, Vipergen deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Vipergen ApS, Copenhagen, Denmark Business: Pharmaceuticals Vipergen will use its small molecule discovery platform to identify hits and leads for undisclosed targets from…

    Published on 1/25/2016
  • Biotie, Acorda deal

    Biotie Therapies Corp. (HSE:BTH1V;NASDAQ:BITI), Turku, Finland Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Business: Neurology Acorda will acquire Biotie for EUR23.57 per ADS in cash .The companies said the …

    Published on 1/25/2016
  • CytomX, Bristol-Myers deal

    CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer CytomX received a $10 million milestone payment from Bristol-Myers Squibb under a …

    Published on 1/25/2016
  • Dual Therapeutics, Bristol-Myers deal

    Dual Therapeutics LLC, Cleveland, Ohio Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Dual Therapeutics granted Bristol-Myers Squibb exclusive, worldwide rights to develop and commercialize …

    Published on 1/25/2016
  • Genetic Analysis, Biohit deal

    Genetic Analysis A/S, Sagheling, Norway Biohit Oyj (HSE:BIOBV), Helsinki, Finland Business: Diagnostic Genetic Analysis granted Biohit the right to sell Genetic Analysis Dysbiosis Test, which can identify imbalances in …

    Published on 1/25/2016
  • Incyte, AstraZeneca deal

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer The companies partnered to conduct a Phase I/II trial to evaluate Incytes INCB39110 with AstraZenecas …

    Published on 1/25/2016
  • Ipsen, Nestle deal

    Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Nestle S.A. (SIX:NESN), Vevey, Switzerland Business: Dermatology Ipsen and Nestles Galderma unit again amended a 2007 deal. Ipsen now granted Galderma …

    Published on 1/25/2016
  • J&J, University of Dundee, University of Edinburgh, University of Oxford deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. University of Dundee, Dundee, U.K. University of Edinburgh, Edinburgh, U.K. University of Oxford, Oxford, U.K. Business: Autoimmune, Cancer, High throughput screening …

    Published on 1/25/2016
  • Kymab, University of Texas MD Anderson Cancer Center deal

    Kymab Ltd., Cambridge, U.K. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Kymab partnered with the centers Oncology Research and Biologics and Immunotherapy Translation (ORBIT) unit to …

    Published on 1/25/2016
  • Novartis, Chugai deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Cancer Chugai and Novartis will terminate a 2006 deal to co-market breast cancer drug Femara …

    Published on 1/25/2016
  • OncoFusion Therapeutics, Medivation deal

    OncoFusion Therapeutics Inc., Ann Arbor, Mich. Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Business: Cancer OncoFusion will reacquire rights to its compounds targeting BET bromodomain proteins identified and …

    Published on 1/25/2016
  • Promiliad, Spero Therapeutics, University of Connecticut deal

    Promiliad Biopharma Inc., Alberton, Mont. Spero Therapeutics LLC, Cambridge, Mass. University of Connecticut, Storrs, Conn. Business: Infectious Promiliad granted Spero a worldwide, exclusive sublicense to develop and …

    Published on 1/25/2016
  • Rani Therapeutics, AstraZeneca deal

    Rani Therapeutics LLC, San Jose, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Endocrine/Metabolic Rani and AstraZenecas MedImmune LLC unit partnered for two years to evaluate Ranis oral drug …

    Published on 1/25/2016
  • Stanford University, Medgenics deal

    Stanford University, Stanford, Calif. Medgenics Inc. (NYSE-M:MDGN), Wayne, Pa. Business: Gene/Cell therapy, Hematology The university granted Medgenics an exclusive, worldwide license to Stanfords autologous ex vivo …

    Published on 1/25/2016
  • University of Dundee, University of Edinburgh, University of Oxford deal

    University of Dundee, Dundee, U.K. University of Edinburgh, Edinburgh, U.K. University of Oxford, Oxford, U.K. Business: High throughput screening The universities launched the National Phenotypic Screening Centre (NPSC…

    Published on 1/25/2016
  • Valeant Pharmaceuticals, Swedish Orphan Biovitrum deal

    Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Gastrointestinal Valeants PharmaSwiss S.A. division granted Swedish Orphan…

    Published on 1/25/2016
  • Vectura, Boehringer Ingelheim deal

    Vectura Group plc (LSE:VEC), Chippenham, U.K. Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary Vectura disclosed that its partner for a 2011 deal to develop and commercialize VR315 is Boehringers Roxane…

    Published on 1/25/2016
  • Vernalis, Corvus Pharmaceuticals deal

    Vernalis plc (LSE:VER), Winnersh, U.K. Corvus Pharmaceuticals Inc., Burlingame, Calif. Business: Pharmaceuticals Vernalis disclosed that Corvus is the company to which Vernalis granted exclusive, worldwide rights to …

    Published on 1/25/2016
  • AbVitro, Juno Therapeutics deal

    AbVitro Inc., Boston, Mass. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Business: Cancer, High throughput screening Juno acquired AbVitro, gaining AbVitros high throughput, single-cell sequencing platform that …

    Published on 1/18/2016
  • Affymetrix, Thermo Fisher deal

    Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Business: Supply/Service, Other Thermo Fisher will acquire cellular and genetic analysis tools company …

    Published on 1/18/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993